HR17031
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 16
Of
16
Go to page
1
August 27, 2025
Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomised, parallel three-arm, treat-to-target trial.
(PubMed, Diabetes Obes Metab)
- "HR17031 is effective and well-tolerated in patients with type 2 diabetes uncontrolled on metformin with or without a second oral antidiabetic drug."
Journal • P2 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus
July 03, 2025
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
(clinicaltrials.gov)
- P3 | N=401 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Trial primary completion date: Mar 2025 ➔ Aug 2025
Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 18, 2025
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
(clinicaltrials.gov)
- P3 | N=401 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 12, 2025
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
(clinicaltrials.gov)
- P3 | N=393 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
May 21, 2024
Benefits of HR17031, a Fixed-Ratio Combination of INS068 and SHR20004, vs. Its Components Alone in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Oral Antidiabetic Drug(s) (OADs)
(ADA 2024)
- "This trial assessed efficacy and safety of HR17031 vs INS068 and SHR20004 in pts with T2D. In this randomized phase 2 trial, 455 Chinese adults with T2D (HbA1c 7.5%-11.0%; previous metformin±another OAD) were randomized (2:2:1) to daily injections of HR17031 (n = 183), INS068 (n = 182) or SHR20004 (0.12 mg/d; n = 90). HR17031 is effective and well-tolerated in pts with T2D uncontrolled on OAD(s)."
Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus
February 01, 2024
A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
November 18, 2023
A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
October 17, 2023
A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
April 25, 2023
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
(clinicaltrials.gov)
- P2 | N=455 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
October 13, 2022
Pharmacokinetics of HR17031 Injection in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
July 27, 2022
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
(clinicaltrials.gov)
- P2 | N=450 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
April 19, 2022
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
(clinicaltrials.gov)
- P2 | N=450 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 23, 2022
A Trial of HR17031 Injection With Renal Insufficiency
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus
December 09, 2021
A Trial of HR17031 Injection With Hepatic Insufficiency
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Clinical • New P1 trial • Diabetes • Hepatitis C • Liver Failure • Metabolic Disorders • Type 2 Diabetes Mellitus
September 23, 2021
Pharmacokinetics of HR17031 Injection in Healthy Subjects
(clinicaltrials.gov)
- P1; N=24; Active, not recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
September 02, 2021
Pharmacokinetics of HR17031 Injection in Healthy Subjects
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 16
Of
16
Go to page
1